Nektar Therapeutics (NKTR) vs Palvella Therapeutics, Inc. (PVLA)

Nektar Therapeutics and Palvella Therapeutics, Inc. are both Biotechnology companies. Nektar Therapeutics and Palvella Therapeutics, Inc. are of similar size ($2.1B and $2.1B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 142.9% against −27.2%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −287.8%) and the higher return on invested capital (0.00% vs −40.2%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 11 and Nektar Therapeutics on 5.

Valuation

Metric NKTR PVLA Biotechnology median
P/E n/m n/m 7.88
P/S 34.55 48.46 11.47
P/B 2.09 9.15 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 26.50 42.37 10.73
Earnings yield (11.74%) (3.50%) (28.84%)
Free cash flow yield (12.41%) (1.62%) (23.03%)

Profitability

Metric NKTR PVLA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (257.80%) 0.00% 0.00%
Net margin (287.84%) 0.00% 0.00%
Free cash flow margin (428.72%) 0.00% 0.00%
Return on equity (35.75%) (46.63%) (57.72%)
Return on assets (24.12%) (37.70%) (49.22%)
Return on invested capital (40.20%) 0.00% 0.00%

Growth

Metric NKTR PVLA Biotechnology median
Revenue growth (TTM) (27.15%) 142.89% 5.64%
EPS growth (last fiscal year) (11.89%) 52.62% —
Revenue growth, 5-year CAGR (18.43%) 8.03% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NKTR PVLA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.42 21.18 4.73
Net debt to EBITDA 1.77 1.50 0.96

Dividend

Metric NKTR PVLA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NKTR PVLA Biotechnology median
Market cap 2.14b 2.10b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack